Switch theme
Sign up to access all valuation multiples
Medacta Group SA is involved in developing, manufacturing and distributing orthopedic and neurosurgical medical devices. The company offers solutions for Hip, Knee, Shoulder and Spine. The majority of the company's revenue is generated from Europe, Middle East, and Africa (EMEA) and the rest from other regions.
1999
1.9K+
LTM Revenue $622M
LTM EBITDA $169M
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medacta Group has a last 12-month revenue of $622M and a last 12-month EBITDA of $169M.
In the most recent fiscal year, Medacta Group achieved revenue of $668M and an EBITDA of $182M.
Medacta Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medacta Group valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $578M | $668M | XXX | XXX | XXX |
| Gross Profit | $345M | $393M | XXX | XXX | XXX |
| Gross Margin | 60% | 59% | XXX | XXX | XXX |
| EBITDA | $139M | $182M | XXX | XXX | XXX |
| EBITDA Margin | 24% | 27% | XXX | XXX | XXX |
| Net Profit | $52.3M | $53.6M | XXX | XXX | XXX |
| Net Margin | 9% | 8% | XXX | XXX | XXX |
| Net Debt | $125M | $159M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Medacta Group's stock price is CHF 119 (or $134).
Medacta Group has current market cap of CHF 2.4B (or $2.7B), and EV of CHF 2.6B (or $2.9B).
See Medacta Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $2.7B | XXX | XXX | XXX | XXX | $4.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Medacta Group has market cap of $2.7B and EV of $2.9B.
Medacta Group's trades at 4.4x LTM EV/Revenue multiple, and 16.2x LTM EBITDA.
Analysts estimate Medacta Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medacta Group and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $2.9B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 16.0x | XXX | XXX | XXX |
| P/E | 32.5x | XXX | XXX | XXX |
| P/E/Growth | 2.2x | XXX | XXX | XXX |
| EV/FCF | 1044.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedacta Group's NTM/LTM revenue growth is 12%
Medacta Group's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Medacta Group's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medacta Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medacta Group and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 36% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 52% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medacta Group acquired XXX companies to date.
Last acquisition by Medacta Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Medacta Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medacta Group founded? | Medacta Group was founded in 1999. |
| Where is Medacta Group headquartered? | Medacta Group is headquartered in Switzerland. |
| How many employees does Medacta Group have? | As of today, Medacta Group has 1.9K+ employees. |
| Is Medacta Group publicy listed? | Yes, Medacta Group is a public company listed on SWX. |
| What is the stock symbol of Medacta Group? | Medacta Group trades under MOVE ticker. |
| When did Medacta Group go public? | Medacta Group went public in 2019. |
| Who are competitors of Medacta Group? | Similar companies to Medacta Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Medacta Group? | Medacta Group's current market cap is $2.7B |
| What is the current revenue of Medacta Group? | Medacta Group's last 12-month revenue is $622M. |
| What is the current EBITDA of Medacta Group? | Medacta Group's last 12-month EBITDA is $169M. |
| What is the current EV/Revenue multiple of Medacta Group? | Current revenue multiple of Medacta Group is 4.4x. |
| What is the current EV/EBITDA multiple of Medacta Group? | Current EBITDA multiple of Medacta Group is 16.2x. |
| What is the current revenue growth of Medacta Group? | Medacta Group revenue growth between 2023 and 2024 was 16%. |
| Is Medacta Group profitable? | Yes, Medacta Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
